Member Info for miavoce

I was at my daughter's graduation and she was one of the professors present at the ceremony.

Looks like Angle are the most recently added company to their Global Partners section. I wonder why there has been no announcement on this.

I met Lindy's sister today. I'm taking that as a good omen.

Interesting tweet from Angle:-

'Find #ANGLE at Precision Med Expo & Summit from 24-25th May where we will be joining Integrated Gulf Biosystems on stand C06 to demonstrate our patented #Parsortix® technology. (For Research Use Only. Not For Use in Diagnostic Procedures) Visit hxxps://precisionmedexpo.com'

https://twitter.com/Parsortix/status/1528780119678062592

I wonder if we about to see another partnership being announced ?

Hi BucksLad

'Clearly Angle board assumes its now just a buereaucratic delay caused by initial lack of reagents and covid absences at the FDA labs and office.'

The lack of reagents has nothing to do with the FDA approval. It relates to the analysis of the samples in the ovarian trial. Regarding the FDA labs, I am not aware that the FDA are undertaking their own hands on trial of Parsortix and the company have never indicated that this is taking place, so I think you are perhaps mistaken on this. The impact of Covid has no doubt delayed things.

Another variation of the DNA approach.

Looks to me like the page was created by this lady who is looking to address the lack of female scientists covered on Wikipedia ;-

https://en.wikipedia.org/wiki/Jess_Wade

I expect that sell was being worked throughout the day, hence the early fall in SP today.

The fact that Scancell are presenting their Glycan/Avidimab (Glmab) portfolio at such a prestigious conference must indicate that they are now very confident in the platform. They are putting their goods in the shop window - ready for deals to be done.

Kashdog, scousemark, Balckfordian - thanks for your replies. I guess that the upside of doing the drawdown from the SIPP and using the cash to buy shares in the ISA is that when the value of the SIPP is next assessed (for tax purposes) it would minimise the risk of the SIPP being over the lifetime allowance if the Scancell shares appreciate greatly in value ?

Hi scousemark - do you have to pay any tax when moving shares from SIPP to ISA (given that the funds used for the purchase in the SIPP would not have attracted income tax) ?

Nice one Burble. Given how well you have communicated complex matters on this board I can't think of a better person to be reaching out to the media.

25/4

I notice that the trinity note contains the following regarding the SCIB1 trial:

'The study could complete enrolment by mid- to late-2022, with clinical data following some months later.'

This implies that further patient shave been recruited - if we were still stuck at one patient then there is no way that recruitment would be expected to complete this year. Interesting that they go so far as indicating that recruitment could be done by mid 2022 - must being seeing some good momentum in recruitment for this to be a possibility.

I do recall Lindy saying that Professor Christian Ottensmeier had patients lined up for as soon as the trial started so assuming that these patients have not succumbed in the meantime the first patient dosed notification may come within days.

Hi Cleanerworld - if you go on the other site (starts with A then D then V the F then N) you are able to message other posters using the message facility. You can sign up for free. You are welcome to message me on that site if you wish (I have the same user name as on this site).

His LinkedIn page doesn't even mention scan cell - all very odd.

Angle are focusing all their efforts on the US. Once the US is dealt with I daresay they will look at entry to other markets such as UK.

Some pretty chunky delays buys today. Hopefully we've found the bottom - let the recovery commence.

Lab accreditation has no relationship to the FDA approval. FDA approval purely relates to the capability of the device to extract MBC CTC's from blood.